Drug recall · February 27, 2019
Temozolomide Capsules recall
Why: Failed dissolution specifications
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Temozolomide Capsules, 5 mg, packaged in a) 5-count bottle (NDC 43975-252-05) b) 14-count bottle (NDC 43975-252-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071
- Lots / codes
Lot #: a) 18J043A, Exp 09/30/2020, b) 18J043B, Exp 09/30/2020
- Quantity
- a) 2,413 bottles b) 3,355 bottles
- Company
- Amerigen Pharmaceuticals Inc., Lyndhurst, NJ
- Distribution
- Product was distributed to 4 wholesalers/distributors and 1 retail account who may have further distribute the product throughout the United States.
- Initiated
- February 19, 2019 · Voluntary: Firm initiated
- Classified
- February 20, 2019
- Reported
- February 27, 2019
- Ended
- December 17, 2019
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Temozolomide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.